Web Stats Provided By Google Analytics

Thursday, September 28, 2017

Cantor Fitzgerald Reiterates Buy Rating for CymaBay Therapeutics Inc.

... L.P. bought a new position in CymaBay Therapeutics in the second quarter worth approximately $242,000. Finally, Ardsley Advisory Partners grew its stake in CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns ...
http://ift.tt/2xF2Cts

No comments:

Post a Comment

Popular Ardsley Roundup Posts